IsoRay Inc. (AMEX: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation video by Cornell Weill demonstrating their techniques in the successful treatment of metastatic brain cancers using IsoRay's patented Cesium-131 (Cs-131) sutured seeds.
Dr. Theodore H. Schwartz and Dr. Gabriella Wernicke , both of Weill Cornell Medical Center, presented their findings for the membership of The Society of Neuro-Oncology (SNO), titled "The study of Neurosurgical Resection and Intra-operative Cesium-131 Radio-isotope Brachytherapy in Patients with newly Diagnosed Brain Metastases," available at http://www.isoray.com/assets/Updated_SNO_Poster.pdf. In the study, which showed Cesium-131's relative effectiveness in treating these tumors compared to other common treatments, the seeded sutures were placed within the resected tumor bed at the time of surgery to provide immediate radiation therapy to it and to a margin depth of 5 mm which is dosed to prevent tumor reoccurrence.
A metastatic, or secondary, brain tumor is one that begins as cancer in another part of the body. Some of the cancer cells may be carried to the brain by the blood or lymphatic fluid, or may spread from adjacent tissue. Metastatic brain tumors are often referred to as lesions or brain metastases. Metastatic brain tumors are the most common brain tumors.